Neoadjuvant Chemotherapy in Non Small Cell Lung Cancer (NSCLC) Stages IB, IIA, IIB, and IIIA/T3

Neoadjuvant Chemotherapy in Resectable NSCLC Stages IB, IIA, IIB, and IIIA/T3 But Not IIIA/N2

Status

Terminated

Phases

Phase 3

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT00273507

Enrollment

270

Registered

2006-01-09

Start date

1998-01-31

Completion date

2006-01-31

Last updated

2009-09-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Non-small Cell Lung Cancer

Keywords

Non-small cell lung cancer, neoadjuvant, resection

Brief summary

Randomised trial of chemotherapy or not before surgery in early resectable stages of NSCLC (IB, IIA, IIB, and IIIA/N2).

Detailed description

Randomisation between 3 courses of neoadjuvant Carboplatin plus Paclitaxel or no chemotherapy before surgery.

Interventions

DRUGCarboplatin and Paclitaxel

Study design

Allocation

RANDOMIZED

Intervention model

SINGLE_GROUP

Primary purpose

TREATMENT

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

18 Years to 75 Years

Healthy volunteers

Inclusion criteria

* NSCLC * Stages IB, IIA, IIB, IIIA/T3 * Lung function test allowing surgery * Age 18-75 years

Exclusion criteria

* Poor lung function * Performance status 3-4 * Mediastinal lymph node involvement

Design outcomes

Primary

Measure	Time frame
Survival	—

Secondary

Measure	Time frame
Time to progression	—
Complete resection rate	—

Countries

Denmark

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026